Rise and Fall of Bedrocan: Pioneer of European Medical Cannabis Closes

Bedrocan's bankruptcy in 2026 marks the end of an era in European medical cannabis, as the pioneering Dutch cultivator faces closure despite decades of advancing therapeutic cannabinoid research and patient access. The company's founder reveals how bureaucratic obstacles, regulatory constraints, and compliance burdens ultimately undermined the organization's operations. Bedrocan's legacy includes establishing GMP-certified cannabis cultivation standards and providing evidence-based medical-grade strains for conditions like chronic pain, multiple sclerosis, and epilepsy. This closure reflects broader tensions between pharmaceutical-grade cannabis innovation and restrictive European regulations that continue to challenge the medical cannabis industry.